TCGA-A7-A6VY-01A-12R-A33J-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 9
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.540
- INTERFERON_ALPHA_RESPONSE+0.470
- INTERFERON_GAMMA_RESPONSE+0.460
- E2F_TARGETS+0.430
- INFLAMMATORY_RESPONSE+0.430
- ALLOGRAFT_REJECTION+0.410
- IL6_JAK_STAT3_SIGNALING+0.410
- G2M_CHECKPOINT+0.380
- GLYCOLYSIS+0.360
- HYPOXIA+0.350
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.370
- PROTEIN_SECRETION-0.370
- UV_RESPONSE_DN-0.270
- ANDROGEN_RESPONSE-0.240
- ADIPOGENESIS-0.220
- FATTY_ACID_METABOLISM-0.210
- PEROXISOME-0.210
- OXIDATIVE_PHOSPHORYLATION-0.190
- ESTROGEN_RESPONSE_LATE-0.160
- BILE_ACID_METABOLISM-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0B3-01A-11R-A056-07 | — | E | 0.921 |
| 2 | 20060013.TNBC | — | E | 0.906 |
| 3 | 20050099.TNBC | — | D | 0.889 |
| 4 | TCGA-E9-A3QA-01A-61R-A22K-07 | — | D | 0.886 |
| 5 | TCGA-OL-A66I-01A-21R-A29R-07 | — | D | 0.862 |
| 6 | TCGA-EW-A1P4-01A-21R-A144-07 | — | E | 0.858 |
| 7 | TCGA-PL-A8LZ-01A-31R-A36F-07 | — | D | 0.845 |
| 8 | TCGA-AO-A129-01A-21R-A10J-07 | — | E | 0.840 |
| 9 | TCGA-S3-AA10-01A-21R-A41B-07 | — | E | 0.839 |
| 10 | R317 | — | — | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.460 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.430 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.430 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.360 | Inavolisib | — uncovered |
| HYPOXIA | 0.350 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.330 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.260 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.240 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.240 | Inavolisib | — uncovered |